| Bioactivity | Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1]. | ||||||||||||
| Target | pKi: 8.1 (p38α), 7.6 (p38β) | ||||||||||||
| In Vivo | In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β)[1]. | ||||||||||||
| Name | Losmapimod | ||||||||||||
| CAS | 585543-15-3 | ||||||||||||
| Formula | C22H26FN3O2 | ||||||||||||
| Molar Mass | 383.46 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. [2]. Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8. |
Losmapimod
CAS: 585543-15-3 F: C22H26FN3O2 W: 383.46
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.